Your browser doesn't support javascript.
COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran.
Nabavi, Seyed Massood; Mehrabani, Mehrnoosh; Ghalichi, Leila; Nahayati, Mohammad Ali; Ghaffari, Mehran; Ashtari, Fereshteh; Mohammadianinejad, Seyed Ehsan; Karimi, Shahedeh; Faghani, Leila; Yazdanbakhsh, Sepideh; Najafian, Abbas; Shahpasand, Koorosh; Vosough, Massoud.
  • Nabavi SM; Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
  • Mehrabani M; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran 1665659911, Iran.
  • Ghalichi L; Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
  • Nahayati MA; Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
  • Ghaffari M; Mental Health Research Center, Psychosocial Health Research Institute, Iran University of Medical Sciences, Tehran 1449614535, Iran.
  • Ashtari F; Neurology Department, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran.
  • Mohammadianinejad SE; Neurology Department, Shahid Beheshti University of Medical Sciences, Tehran 1983969411, Iran.
  • Karimi S; Neurology Department, Isfahan University of Medical Sciences, Isfahan 73461-81746, Iran.
  • Faghani L; Neurology Department, Jondishapour University of Medical Sciences, Ahvaz 15794-61357, Iran.
  • Yazdanbakhsh S; Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
  • Najafian A; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran 1665659911, Iran.
  • Shahpasand K; Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
  • Vosough M; Arya Group for Treatment and Research in Multiple Sclerosis, Tehran 1435864464, Iran.
Vaccines (Basel) ; 10(1)2022 Jan 17.
Article in English | MEDLINE | ID: covidwho-1625559
ABSTRACT
Multiple sclerosis (MS) is a chronic, predominantly immune-mediated degenerative disease of the central nervous system. Due to prolonged use of immunomodulatory and immunosuppressive medications, vaccine hesitancy could be common among MS patients. Our main aim in the current study was to evaluate the willingness and acceptability of COVID-19 vaccination in patients with MS. In our multicenter cross-sectional questionnaire-based clinical study, 892 patients completed the questionnaire between May to June 2021. The questionnaire consisted of demographic data, MS disease-related factors, history of COVID-19 infection/vaccination, and any existing comorbidities. Statistical analysis was performed using SPSS software version 19. Overall, 68% of the participants expressed willingness to be vaccinated. Major causes of vaccine refusal in our patients were the fear of reducing the efficacy of disease modifying drugs (DMDs) upon vaccination as well as distrusting the vaccines and overestimation bias in the power of their innate immunity and potential COVID-19 resistance. Some demographic factors affected vaccination enthusiasm in our study. Our findings did not show significant correlation between the age and comorbidity and vaccine willingness. Only one-third of our patients received their vaccine information from healthcare providers. The majority of them received these data from official broadcasting channels and social media. However, despite several concerns, the willingness of COVD-19 vaccination in the Iranian MS patients is remarkable.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10010135

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10010135